AN2 Therapeutics (ANTX) closed at $5.84 on Sep 3, 2026, down 1.8% on the day. The stock is up 0.0% over the past month, up 40.0% over three months, up 412.3% year to date and up 352.7% over the past year. It trades 18.8% below its 52-week high of $7.19 and 484.0% above its 52-week low of $1.00. The close sits above its 50-day moving average ($5.29) and above its 200-day moving average ($3.36).
Form 4 filings over the last 90 days show 1 open-market purchase and 9 open-market sales by insiders.
Yes — the Sep 3, 2026 close of $5.84 is 74.0% above the 200-day average of $3.36.
ANTX closed 18.8% below its 52-week high of $7.19.
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials; and has various research programs targeting the development of novel compounds in oncology and infectious disease based on its boron chemistry platform. It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize compounds and products, including epetraborole for the treatment, diagnosis, or prevention of various human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize compounds and products comprising epetraborole in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases; and GSK plc for the development of new therapies for TB. AN2 Therapeutics, Inc. was incorporated in 2017 and is headquartered in Menlo Park, California.
